Abstract
Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disorder of early childhood; it is characterized by hepatosplenomegaly and organ infiltration due to excessive proliferation of cells of the monocytic and granulocytic lineages. Approximately 85% of JMML patients harbor in their leukemia cells either somatic or germline mutations in the genes PTPN-11, NRAS, KRAS, NF1, or CBL. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the therapy of choice for the majority of affected children. Available data indicate that transplantation from an HLA-identical sibling or a matched unrelated volunteer can cure more than 50% of patients. A similar proportion of children with JMML, especially when transplanted from donors with limited HLA disparity, can be cured with umbilical cord blood transplantation, which can represent a suitable option for children with JMML lacking either a related or an unrelated HSCT donor.
Lingua originale | English |
---|---|
Titolo della pubblicazione ospite | Thomas' Hematopoietic Cell Transplantation: Fifth Edition |
Pagine | 554-565 |
Numero di pagine | 12 |
Volume | 1-2 |
DOI | |
Stato di pubblicazione | Pubblicato - 2016 |
Keywords
- CBL
- Juvenile myelomonocytic leukemia
- Leukemia recurrence
- Splenectomy
- PTPN-11
- RAS pathway
- Second allograft
- Neurofibromatosis type 1